NCT05066685

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 18,457 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.

Detailed description

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020. * Identification period of the index period: 10/10/2019 to 04/30/2020 * Index date: Date of enrollment in the PSS program * Study Period: 10/10/2019 to 04/30/2020

Conditions

• Age-related Macular Degeneration (AMD)

Interventions

Type	Name	Description
OTHER	All participants	All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program

Timeline

• Start date: 2020-08-11
• Primary completion: 2020-09-25
• Completion: 2020-09-25
• First posted: 2021-10-04
• Last updated: 2021-10-12

Locations

1 site across 1 country: United States